Angiogenesis-related gene expression profile with independent prognostic value in advanced ovarian carcinoma

PLoS ONE

Volumn 3, Issue 12, 2008, Pages

  Mendiola, Marta ^a   Barriuso, Jorge ^a   Redondo, Andrés ^a   Mariño Enríquez, Adrián ^a   Madero, Rosario ^a   Espinosa, Enrique ^a   Vara, Juan Angel Fresno ^a   Sánchez Navarro, Iker ^a   Hernández Cortes, Ginés ^b   Zamora, Pilar ^a   Pérez Fernández, Elia ^a   Miguel Martín, María ^a   Suárez, Asunción ^a   Palacios, José ^b   González Barón, Manuel ^a   Hardisson, David ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; CARBOPLATIN; PACLITAXEL; RNA;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GENETICS; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; FEMALE; FOLLOW UP; GENE EXPRESSION PROFILING; HAZARD RATIO; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CARCINOMA; OVERALL SURVIVAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; CARCINOMA; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOVASCULARIZATION (PATHOLOGY); OVARY TUMOR;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; PROGNOSIS; RNA;

EID: 58149202145     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0004051     Document Type: Article

References (38)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2008) Cancer statistics, 2008. CA Cancer J Clin 58: 71-96.
2. Qazi F, McGuire WP (1995) The treatment of epithelial ovarian cancer. CA Cancer J Clin 45: 88-101.
3. Agarwal R, Kaye SB (2003) Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 3: 502-516.
4. Friedlander ML (1998) Prognostic factors in ovarian cancer. Semin Oncol 25: 305-314.
5. Cannistra SA (2004) Cancer of the ovary. N Engl J Med 351: 2519-2529.
6. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, et al. (1997) Comparison of combination therapy with paclitaxel and cisplatin versus cyclophosphamide and cisplatin in patients with suboptimal stage III and stage IV ovarian cancer: a Gynecologic Oncology Group study. Semin Oncol 24: S2.
7. du BA, Luck HJ, Meier W, Adams HP, Mobus V, et al. (2003) A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95: 1320-1329.
8. Folkman J (1990) What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82: 4-6.
9. Cannistra SA, Matulonis UA, Penson RT, Hambleton J, Dupont J, et al. (2007) Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 25: 5180-5186.
10. Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI (2007) Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 25: 5165-5171.
11. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, et al. (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3: RESEARCH0034.
12. Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: e45.
13. You B, Perrin P, Freyer G, Ruffion A, Tranchand B, et al. (2008) Advantages of prostate-specific antigen (PSA) clearance model over simple PSA half-life computation to describe PSA decrease after prostate adenomectomy. Clin Biochem 41: 785-795.
14. Simon R, Wang SJ (2006) Use of genomic signatures in therapeutics development in oncology and other diseases. Pharmacogenomics J 6: 166-173.
15. Spentzos D, Levine DA, Kolia S, Otu H, Boyd J, et al. (2005) Unique gene expression profile based on pathologic response in epithelial ovarian cancer. J Clin Oncol 23: 7911-7918.
16. Spentzos D, Levine DA, Ramoni MF, Joseph M, Gu X, et al. (2004) Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J Clin Oncol 22: 4700-4710.
17. Helleman J, Jansen MP, Span PN, van Staveren IL, Massuger LF, et al. (2006) Molecular profiling of platinum resistant ovarian cancer. Int J Cancer 118: 1963-1971.
18. Hartmann LC, Lu KH, Linette GP, Cliby WA, Kalli KR, et al. (2005) Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy. Clin Cancer Res 11: 2149-2155.
19. Bonome T, Levine DA, Shih J, Randonovich M, Pise-Masison CA, et al. (2008) A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. Cancer Res 68: 5478-5486.
20. Olivier RI, van Beurden M, Veer LJ (2006) The role of gene expression profiling in the clinical management of ovarian cancer. Eur J Cancer 42: 2930-2938.
21. Fehrmann RS, Li XY, van der Zee AG, de Jong S, Te Meerman GJ, et al. (2007) Profiling studies in ovarian cancer: a review. Oncologist 12: 960-966.
22. Cronin M, Pho M, Dutta D, Stephans JC, Shak S, et al. (2004) Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. Am J Pathol 164: 35-42.
23. Antonov J, Goldstein DR, Oberli A, Baltzer A, Pirotta M, et al. (2005) Reliable gene expression measurements from degraded RNA by quantitative real-time PCR depend on short amplicons and a proper normalization. Lab Invest 85: 1040-1050.
24. Borgstrom P, Hillan KJ, Sriramarao P, Ferrara N (1996) Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Res 56: 4032-4039.
25. Abu-Jawdeh GM, Faix JD, Niloff J, Tognazzi K, Manseau E, et al. (1996) Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms. Lab Invest 74: 1105-1115.
26. Goodheart MJ, Ritchie JM, Rose SL, Fruehauf JP, De Young BR, et al. (2005) The relationship of molecular markers of p53 function and angiogenesis to prognosis of stage I epithelial ovarian cancer. Clin Cancer Res 11: 3733-3742.
27. Duncan TJ, Al Attar A, Rolland P, Scott IV, Deen S, et al. (2008) Vascular endothelial growth factor expression in ovarian cancer: a model for targeted use of novel therapies? Clin Cancer Res 14: 3030-3035.
28. Deeds J, Cronin F, Duncan LM (2000) Patterns of melastatin mRNA expression in melanocytic tumors. Hum Pathol 31: 1346-1356.
29. Hefler LA, Mustea A, Konsgen D, Concin N, Tanner B, et al. (2007) Vascular endothelial growth factor gene polymorphisms are associated with prognosis in ovarian cancer. Clin Cancer Res 13: 898-901.
30. Husain A, He G, Venkatraman ES, Spriggs DR (1998) BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). Cancer Res 58: 1120-1123.
31. Yuan SS, Lee SY, Chen G, Song M, Tomlinson GE, et al. (1999) BRCA2 is required for ionizing radiation-induced assembly of Rad51 complex in vivo. Cancer Res 59: 3547-3551.
32. Henriksen R, Funa K, Wilander E, Backstrom T, Ridderheim M, et al. (1993) Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms. Cancer Res 53: 4550-4554.
33. Lassus H, Sihto H, Leminen A, Nordling S, Joensuu H, et al. (2004) Genetic alterations and protein expression of KIT and PDGFRA in serous ovarian carcinoma. Br J Cancer 91: 2048-2055.
34. Versnel MA, Haarbrink M, Langerak AW, De Laat PA, Hagemeijer A, et al. (1994) Human ovarian tumors of epithelial origin express PDGF in vitro and in vivo. Cancer Genet Cytogenet 73: 60-64.
35. Schindl M, Schoppmann SF, Strobel T, Heinzl H, Leisser C, et al. (2003) Level of Id-1 protein expression correlates with poor differentiation, enhanced malignant potential, and more aggressive clinical behavior of epithelial ovarian tumors. Clin Cancer Res 9: 779-785.
36. Wu Q, Suo Z, Kristensen GB, Baekelandt M, Nesland JM(2006) The prognostic impact of EphB2/B4 expression on patients with advanced ovarian carcinoma. Gynecol Oncol 102: 15-21.
37. Jeong JY, Feldman L, Solar P, Szenajch J, Sytkowski AJ (2008) Characterization of erythropoietin receptor and erythropoietin expression and function in human ovarian cancer cells. Int J Cancer 122: 274-280.
38. Lancaster JM, Dressman HK, Whitaker RS, Havrilesky L, Gray J, et al. (2004) Gene expression patterns that characterize advanced stage serous ovarian cancers. J Soc Gynecol Investig 11: 51-59.